[go: up one dir, main page]

WO2007030580A3 - Agents neuroprotecteurs - Google Patents

Agents neuroprotecteurs Download PDF

Info

Publication number
WO2007030580A3
WO2007030580A3 PCT/US2006/034796 US2006034796W WO2007030580A3 WO 2007030580 A3 WO2007030580 A3 WO 2007030580A3 US 2006034796 W US2006034796 W US 2006034796W WO 2007030580 A3 WO2007030580 A3 WO 2007030580A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
neural
protecting
administering
excitotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/034796
Other languages
English (en)
Other versions
WO2007030580A2 (fr
Inventor
Mary Stenzel-Poore
Susan Stevens
Roger Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
Original Assignee
Oregon Health and Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University filed Critical Oregon Health and Science University
Publication of WO2007030580A2 publication Critical patent/WO2007030580A2/fr
Publication of WO2007030580A3 publication Critical patent/WO2007030580A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés pour protéger des cellules contre des agressions cytotoxiques. Ces procédés consistent à administrer à un sujet une composition qui comprend un agent se liant à un récepteur de type Toll et activant ce dernier, puis éventuellement à administrer un inhibiteur des ASIC. Ces procédés peuvent s'appliquer pour protéger des cellules neurales et non neurales. Cette invention concerne par exemple des procédés pour protéger une cellule neurale contre une lésion cérébrale excitotoxique. Ladite invention concerne également des procédés pour préparer des médicaments utilisés pour traiter de manière prophylactique une lésion excitotoxique, une ischémie et/ou une hypoxie. En outre, cette invention concerne des compositions utilisées dans le cadre desdits procédés.
PCT/US2006/034796 2005-09-09 2006-09-08 Agents neuroprotecteurs Ceased WO2007030580A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71588105P 2005-09-09 2005-09-09
US60/715,881 2005-09-09
US80183006P 2006-05-19 2006-05-19
US60/801,830 2006-05-19

Publications (2)

Publication Number Publication Date
WO2007030580A2 WO2007030580A2 (fr) 2007-03-15
WO2007030580A3 true WO2007030580A3 (fr) 2007-10-11

Family

ID=37836442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034796 Ceased WO2007030580A2 (fr) 2005-09-09 2006-09-08 Agents neuroprotecteurs

Country Status (1)

Country Link
WO (1) WO2007030580A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100130425A1 (en) * 2005-09-09 2010-05-27 Oregon Health & Science University Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
US9370531B2 (en) 2007-08-31 2016-06-21 New York University Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
US10383887B2 (en) 2008-02-20 2019-08-20 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
AU2009311748B2 (en) 2008-11-04 2014-08-21 Index Pharmaceuticals Ab Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells
WO2016183371A1 (fr) 2015-05-13 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Procédés pour le traitement ou la prévention d'une lésion tissulaire ischémique
AU2016295423B2 (en) * 2015-07-17 2020-09-03 Monash University Neuroprotective agents derived from spider venom peptides
JP7547201B2 (ja) 2018-01-12 2024-09-09 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインを標的とするアンチセンスオリゴヌクレオチドおよびその使用
WO2019140231A1 (fr) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Oligonucléotides antisens ciblant l'alpha-synucléine et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007743A2 (fr) * 2002-07-17 2004-01-22 Coley Pharmaceutical Gmbh Utilisation d'acides nucleiques cpg dans les maladies a prions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004007743A2 (fr) * 2002-07-17 2004-01-22 Coley Pharmaceutical Gmbh Utilisation d'acides nucleiques cpg dans les maladies a prions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN XUANMAO ET AL: "The tarantula toxin psalmotoxin 1 inhibits acid-sensing ion channel (ASIC) 1a by increasing its apparent H+ affinity", JOURNAL OF GENERAL PHYSIOLOGY, vol. 126, no. 1, July 2005 (2005-07-01), pages 71 - 79, XP002433748, ISSN: 0022-1295 *
XIONG ZHI-GANG ET AL: "Neuroprotection in ischemia: Blocking calcium-permeable acid-sensing ion channels", CELL, vol. 118, no. 6, 17 September 2004 (2004-09-17), pages 687 - 698, XP002433749, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
WO2007030580A2 (fr) 2007-03-15

Similar Documents

Publication Publication Date Title
EP2322178A3 (fr) Utilisation de TLR ligands pour le traitement d'une lésion excitotoxique, de l'ischémie et/ou de l'hypoxie
WO2007030581A3 (fr) Agents neuroprotecteurs
WO2006102610A3 (fr) Composes bicycloheteroaryle utilises en tant que modulateurs de p2x7 et leurs utilisations
WO2008124085A3 (fr) Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
WO2005070930A3 (fr) Composes de tetrahydrocarboline comme agents anticancereux
WO2015151079A3 (fr) Analogues d'auristatine et leur conjugués avec des molécules de liaison cellulaire
IL207038A (en) History of Diazaspiro [5.5] Undecan, Pharmaceuticals Containing them, and their use in the preparation of drugs for the treatment or reduction of the risk of disease or inflammatory condition
WO2007109192A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2012143497A3 (fr) Nouveaux conjugués liant-principe actif (adc) et leur utilisation
WO2009031106A3 (fr) Utilisation d'une combinaison d'hespéridine et d'un micro-organisme pour influer sur la fonction de barrière de la peau
WO2007109172A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109154A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 modulators et leurs utilisations
WO2008023362A3 (fr) Traitement du cancer
WO2008103847A3 (fr) Compositions à base de composés polycycliques pontés pour l'inhibition et le traitement de maladies
WO2009002867A3 (fr) Forme posologique à unités multiples contenant un agent thérapeutique en combinaison avec un complément alimentaire
WO2010062581A3 (fr) Composition botanique pour une réparation cutanée optimisée et utilisations associées
WO2010093789A3 (fr) Compositions combinatoires et procédés pour le traitement du cancer
WO2007109182A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2009002808A3 (fr) Composés de quinazolinone et leurs méthodes d'utilisation
WO2008079993A3 (fr) Combinaisons d'oxyde nitrique et de sulfure et leurs procédés d'utilisation et de fabrication
WO2007030580A3 (fr) Agents neuroprotecteurs
WO2008142569A3 (fr) Compositions topiques contenant du magaldrate
WO2010019611A3 (fr) Compositions à base de composés polycycliques pontés pour des applications topiques et orales
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
WO2007028022A3 (fr) Nouveaux composes servant de modulateurs de p2x7 et leurs utilisations

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06814265

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06814265

Country of ref document: EP

Kind code of ref document: A2